Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7321568 | 0.89 | ADORA2B (0.41) | MAPTALDH1A1SMN1; SMN2AGTR2LMNA | |
| SCHEMBL7325814 | 0.83 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL588365 | 0.81 | AGTR1 (0.41) | MAPTALDH1A1AGTR1AGTR2 | |
| SCHEMBL7315308 | 0.80 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2AGTR1AGTR2LMNA | |
| SCHEMBL9402002 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2AGTR1AGTR2LMNA | |
| SCHEMBL9871103 | 0.77 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL7820191 | 0.77 | PPARG (0.51) | AGTR1 | |
| SCHEMBL9262511 | 0.76 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNARECQLRAB9A | |
| SCHEMBL7435772 | 0.76 | BCL2 (0.41) | AGTR1 | |
| SCHEMBL7819140 | 0.76 | AGTR1 (0.58) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6071913-A | 2-(1H-TETRAZOL-5-YL)-4'-(AS-TRIAZIN-YLMETHYL)BIPHENYLS; CARDIOVASCULAR DISEASES, ESPECIALLY HYPERTENSION AND CONGESTIVE HEART FAILURE | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2000-06-06 | — | — | US | disclosed |